David A. Edwards | |
---|---|
![]() | |
Born | David A. Edwards April 6, 1961 |
Alma mater | Michigan Technological University, BS Illinois Institute of Technology, PhD |
Scientific career | |
Fields | Biomedical engineering |
Institutions | Harvard University |
Website | davidideas |
David A. Edwards (born April 6, 1961) is an American biomedical engineer, and the founder of Sensory Cloud. [1] [2] He was the Gordon McKay Professor of the Practice of Biomedical Engineering at Harvard University. [3] [4]
Edwards designs inhalable medicines, vaccines and victuals. [5] [6] [7]
In 2001, Edwards was elected a member of the National Academy of Engineering for transfer of scientific principles of engineering to industry, including invention and commercial development of a novel, generic aerosol drug-delivery system.
Edwards studied chemical engineering, receiving a BS from Michigan Technological University in the field in 1983, and a PhD in 1987 from the Illinois Institute of Technology. [8] [9]
Between 1987 and 1995, Edwards held a postdoctoral and lectureship at the Technion in Israel and the Massachusetts Institute of Technology. [10] [11] While at MIT, Robert Langer, a professor at MIT, encouraged Edwards to develop an efficient way for inhalers to deliver medicine to the lungs. [12] Edwards joined the Pennsylvania State University faculty as an Associate Professor of Chemical Engineering in 1995, where he continued to research ways to make medicine inhalable. [13] [14] In 1997, Science published his study on a new type of inhalable aerosol that efficiently delivered drugs to the lungs. [15] [16] Edwards left academia in 1998 when he and Langer founded Advanced Inhalation Research (AIR); the startup was purchased a year later by Alkermes for $114 million. [17] [18] He returned to academia in 2002, joining the Harvard faculty. [19]
Edwards' scientific work in biomedical engineering concerns the research and development of drug delivery platforms for treating infectious diseases in the developing world.[ citation needed ] He was a founder of Advanced Inhalation Research, now part of Alkermes, Inc.,[ citation needed ] of Pulmatrix,[ citation needed ] and of Medicine in Need, an international non-governmental organization aimed at developing new drugs and vaccines for diseases of poverty, such as tuberculosis. [20] [21]
In 2020, Edwards founded the company Sensory Cloud. Sensory Cloud released a nasal inhalable product intended to reduce infected air droplets from viruses like SARS-CoV-2, a strain of coronavirus known to cause COVID-19. [22] [23]
In a February 2021 study in the Proceedings of the National Academy of Sciences of the United States of America , Edwards and his colleagues posited that "exhaled aerosol increases with COVID-19 infection, age, and obesity". [24] [25]
In 2007, Edwards opened "Le Lab" as a space for artists, designers, scientists, and the general public to meet for exhibitions, performances, and discussions in Paris, [26] [27] and then he moved it to 650 East Kendall Street in the Kendall Square area of Cambridge, Massachusetts in 2014. [28] [29] [30] Major exhibitions by artists such as Mark Dion [31] [32] and artist/engineer Chuck Hoberman [33] [34] were shown, as well as innovations developed by Edwards, his associates, and his students. Some of his food-related inventions were available for purchase at Cafe ArtScience, an innovative restaurant associated with Le Laboratoire Cambridge. [35] In December 2019, it was announced that Cafe ArtScience was closing after 5 years of operation, and would be replaced by a new restaurant, called "Senses". [36]
However, the COVID-19 pandemic disrupted these plans, and as of 2022 [update] , both the restaurant and Le Laboratoire Cambridge appear to be inactive or closed, either temporarily or permanently.
Edwards, his wife and three children have lived alternately in Boston and Paris. [37]
Cambridge is a city in Middlesex County, Massachusetts, in the United States. It is a suburb in the Greater Boston metropolitan area, located directly across the Charles River from Boston. The city's population as of the 2020 U.S. census was 118,403, making it the most populous city in the county, the fourth-largest in Massachusetts, behind Boston, Worcester, and Springfield, and ninth-largest in New England. The city was named in honor of the University of Cambridge in Cambridge, England, which was an important center of the Puritan theology that was embraced by the town's founders.
The Massachusetts Institute of Technology (MIT) is a private land-grant research university in Cambridge, Massachusetts. Established in 1861, MIT has played a significant role in the development of many areas of modern technology and science.
Kendall Square is a neighborhood in Cambridge, Massachusetts. The square itself at the intersection of Main Street and Broadway. It also refers to the broad business district east of Portland Street, northwest of the Charles River, north of MIT and south of Binney Street.
In medicine, a nebulizer or nebuliser is a drug delivery device used to administer medication in the form of a mist inhaled into the lungs. Nebulizers are commonly used for the treatment of asthma, cystic fibrosis, COPD and other respiratory diseases or disorders. They use oxygen, compressed air or ultrasonic power to break up solutions and suspensions into small aerosol droplets that are inhaled from the mouthpiece of the device. An aerosol is a mixture of gas and solid or liquid particles.
The MIT Press is a university press affiliated with the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts. The Press has been a pioneer in the Open Access movement in academic publishing and publishes a number of academic journals. The organization also operates the MIT Press Bookstore, which is one of the few retail bookstores run by a university publisher.
Robert Samuel Langer Jr. FREng is an American biotechnologist, businessman, chemical engineer, chemist, and inventor. He is one of the eight Institute Professors at the Massachusetts Institute of Technology.
The MIT Museum, founded in 1971, is located at the Massachusetts Institute of Technology in Cambridge, Massachusetts. It hosts collections of holography, technology-related artworks, artificial intelligence, architecture, robotics, maritime history, and the history of MIT. Its holography collection of 1800 pieces is the largest in the world, though only a few selections from it are usually exhibited. As of 2023, works by the kinetic artist Arthur Ganson are the largest long-running displays. There is a regular program of temporary special exhibitions, often on the intersections of art and technology.
The history of the Massachusetts Institute of Technology can be traced back to the 1861 incorporation of the "Massachusetts Institute of Technology and Boston Society of Natural History" led primarily by William Barton Rogers.
The Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) is the engineering school within Harvard University's Faculty of Arts and Sciences, offering degrees in engineering and applied sciences to graduate students admitted directly to SEAS, and to undergraduates admitted first to Harvard College. Previously the Lawrence Scientific School and then the Division of Engineering and Applied Sciences, the Paulson School assumed its current structure in 2007. Francis J. Doyle III has been its dean since 2015.
Leo Rafael Reif is a Venezuelan American electrical engineer and academic administrator. He previously served as the 17th president of the Massachusetts Institute of Technology from 2012 to 2022, provost of the institute from 2005 to 2012, and dean of the institute's EECS department from 2004 to 2005.
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD). It is delivered as an aerosol formulation through a dry powder inhaler.
Donald E. Ingber is an American cell biologist and bioengineer. He is the founding director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children's Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences. He is also a member of the American Institute for Medical and Biological Engineering, the National Academy of Engineering, the National Academy of Medicine, the National Academy of Inventors, and the American Academy of Arts and Sciences.
Elazer R. Edelman is an American engineer, scientist and cardiologist. He is the Edward J. Poitras Professor in Medical Engineering and Science at the Massachusetts Institute of Technology (MIT), Professor of Medicine at Harvard Medical School and at Brigham and Women's Hospital (BWH), and a practicing cardiologist at BWH. He is the director of MIT's Institute for Medical Engineering and Science (IMES), the Harvard-MIT Biomedical Engineering Center, and the MIT Clinical Research Center. He is also the Program Director of the MIT Graduate Education in Medical Sciences program within the Harvard-MIT Division of Health Sciences and Technology.
Hugo Van Vuuren is a South African entrepreneur and investor. An expert-in-residence at the Harvard School of Engineering and Applied Sciences, he is the co-founder of Work-Bench, an early stage enterprise technology venture fund.
Omid Farokhzad is an Iranian-American physician, scientist, and entrepreneur in the development of nanomedicines. Farokhzad is a Professor of Anesthesiology at Harvard Medical School. Omid Farokhzad is the Chair, Chief Executive Officer and co-founder for Seer, a company focused on deep, unbiased proteomics analysis at scale. The Boston Globe selected him among the top innovators in Massachusetts and the Boston Business Journal selected him among the Health Care Champions for his innovations.
A dental aerosol is an aerosol that is produced from dental instrument, dental handpieces, three-way syringes, and other high-speed instruments. These aerosols may remain suspended in the clinical environment. Dental aerosols can pose risks to the clinician, staff, and other patients. The heavier particles contained within the aerosols are likely to remain suspended in the air for relatively short period and settle quickly onto surfaces, however, the lighter particles may remain suspended for longer periods and may travel some distance from the source. These smaller particles are capable of becoming deposited in the lungs when inhaled and provide a route of diseases transmission. Different dental instruments produce varying quantities of aerosol, and therefore are likely to pose differing risks of dispersing microbes from the mouth. Air turbine dental handpieces generally produce more aerosol, with electric micromotor handpieces producing less, although this depends on the configuration of water coolant used by the handpiece.
Dame Fiona Elizabeth Murray is the Associate Dean for Innovation at the MIT Sloan School of Management. She is a member of the Prime Minister of the United Kingdom's Council for Science and Technology and Vice-Chair of the Board of Directors of the NATO Innovation Fund.
Glycopyrronium bromide/formoterol, sold under the brand name Bevespi Aerosphere, is a combination medication for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is a combination of glycopyrronium bromide and formoterol. It is inhaled.
Pulmonary drug delivery is a route of administration in which patients use an inhaler to inhale their medications and drugs are absorbed into the bloodstream via the lung mucous membrane. This technique is most commonly used in the treatment of lung diseases, for example, asthma and chronic obstructive pulmonary disease (COPD). Different types of inhalers include metered-dose inhalers (MDI), dry powder inhalers (DPI), soft mist inhalers (SMI) and nebulizers. The rate and efficacy of pulmonary drug delivery are affected by drug particle properties, breathing patterns and respiratory tract geometry.
The Wyss Institute for Biologically Inspired Engineering is a cross-disciplinary research institute at Harvard University focused on bridging the gap between academia and industry by drawing inspiration from nature's design principles to solve challenges in health care and the environment. It is focused on the field of biologically inspired engineering to be distinct from bioengineering and biomedical engineering. The institute also has a focus on applications, intellectual property generation, and commercialization.